AVDL · As filed with the SEC
Avadel Pharmaceuticals cash flow statement, by fiscal year
The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (48,832) | (160,276) | (137,464) | (77,329) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 2,681 | 1,766 | 1,493 | 815 |
| Remeasurement of acquisition-related contingent consideration | — | — | — | 0 |
| Remeasurement of financing-related contingent consideration | — | — | — | 0 |
| Amortization of debt discount and debt issuance costs | 0 | 2,796 | 6,052 | 1,248 |
| Changes in deferred taxes | 0 | 0 | 26,025 | (15,666) |
| Share-based compensation expense | 20,387 | 15,811 | 7,013 | 8,872 |
| Gain on sale of Hospital Products | — | — | — | 0 |
| Loss on deconsolidation of subsidiary | — | — | — | 0 |
| Gain from release of certain liabilities | — | — | — | (217) |
| Loss on extinguishment of debt | 0 | 13,129 | — | — |
| Other adjustments | (828) | 1,262 | 2,042 | 1,272 |
| Net changes in assets and liabilities | ||||
| Accounts receivable | (21,994) | (12,103) | — | 0 |
| Inventories | (9,219) | (9,532) | — | 0 |
| Prepaid expenses and other current assets | 416 | (3,127) | 30,815 | (439) |
| Research and development tax credit receivable | — | 1,884 | 30 | 2,796 |
| Accounts payable & other current liabilities | (4,093) | 1,545 | (3,108) | 4,232 |
| Deferred revenue | — | — | — | 0 |
| Accrued expenses | 16,424 | 16,892 | 227 | 895 |
| Earn-out payments for contingent consideration in excess of acquisition-date fair value | — | — | — | 0 |
| Royalty payments for contingent consideration payable in excess of original fair value | — | — | — | 0 |
| Other assets and liabilities | (1,849) | 1,442 | (3,429) | (3,789) |
| Net cash used in operating activities | (46,907) | (128,511) | (70,304) | (77,310) |
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | 0 | 0 | (716) | (26) |
| Proceeds from disposal of property and equipment | — | — | — | 0 |
| Proceeds from the disposition of the Hospital Products | — | 0 | 0 | 16,500 |
| Proceeds from sales of marketable securities | 327,781 | 187,136 | 83,828 | 102,224 |
| Purchases of marketable securities | (276,001) | (237,229) | (3,414) | (61,769) |
| Net cash provided by (used in) investing activities | 51,780 | (50,093) | 79,698 | 56,929 |
| Cash flows from financing activities: | ||||
| Proceeds from the February 2020 private placement | — | — | — | 0 |
| Proceeds from the May 2020 public offering | — | — | — | 0 |
| Proceeds from issuance of shares, net of issue costs | — | — | 25,318 | — |
| At-the-market offering program | 9,250 | 11,913 | — | — |
| Public offering | 0 | 134,151 | — | — |
| Proceeds from stock option exercises and employee share purchase plan | 6,720 | 2,293 | 2,682 | 263 |
| Other financing activities, net | — | — | — | 0 |
| February 2023 Notes | 0 | (17,500) | — | — |
| October 2023 Notes | 0 | (21,165) | — | — |
| Payments for debt issuance costs | 0 | (4,357) | (4,804) | — |
| Payments for extinguishment of February 2023 Notes | — | — | (8,653) | — |
| Proceeds from royalty purchase agreement | 0 | 30,000 | — | — |
| Net cash provided by financing activities | 15,970 | 135,335 | 14,543 | 263 |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | (639) | 455 | (664) | (896) |
| Net change in cash and cash equivalents | 20,204 | (42,814) | 23,273 | (21,014) |
| Cash and cash equivalents at January 1 | 31,167 | 73,981 | 50,708 | 71,722 |
| Cash and cash equivalents at December 31 | 51,371 | 31,167 | 73,981 | 50,708 |
| Supplemental disclosures of cash flow information: | ||||
| Interest paid | 7,181 | 5,250 | 9,660 | 6,469 |
| Income taxes refunded, net | 0 | 0 | (29,058) | 76 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.